[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 26 of about 26
3. Rhomberg W, Stephan H, Böhler F, Erhart K, Eiter H: Radiotherapy and razoxane in advanced bile duct carcinomas. Anticancer Res; 2005 Sep-Oct;25(5):3613-8
MedlinePlus Health Information. consumer health - Bile Duct Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiotherapy and razoxane in advanced bile duct carcinomas.
  • OBJECTIVES: Little is known about the radiation sensitivity of bile duct carcinomas.
  • The current study was undertaken to prospectively assess the objective response rates in bile duct carcinomas treated with radiotherapy and razoxane.
  • They received a total tumor dose of 48 Gy (range 1.7-60) at the ICRU point with single fractions of 1.7 to 2 Gy.
  • Objective tumor responses were seen in 4/4 gallbladder carcinomas (1 CR, 3 PR), 4/5 extrahepatic cholangiocarcinomas (2 CR 2 PR), and 1/5 hepatobiliary cancers (1 PR), leading to an overall response rate of 64%.
  • On an intention-to-treat basis, all patients with different biliary cancer without distant metastases had a median-survival time of 10 months (range 1 to 48) from the start of the radiotherapy; the 1-year survival was 43%.
  • Tolerance to the treatment was fairly good.
  • Obstacles to the treatment were complications of the disease and frequent metastasis.
  • [MeSH-major] Bile Duct Neoplasms / drug therapy. Bile Duct Neoplasms / radiotherapy. Razoxane / therapeutic use
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Agents / therapeutic use. Bile Ducts, Extrahepatic / pathology. Combined Modality Therapy. Female. Gallbladder Neoplasms / drug therapy. Gallbladder Neoplasms / pathology. Gallbladder Neoplasms / radiotherapy. Humans. Male. Middle Aged. Neoplasm Staging. Radiation-Sensitizing Agents / therapeutic use

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16101189.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Radiation-Sensitizing Agents; 5AR83PR647 / Razoxane
  •  go-up   go-down


Advertisement
4. Fukuda S, Okuda K, Imamura M, Imamura I, Eriguchi N, Aoyagi S: Surgical resection combined with chemotherapy for advanced hepatocellular carcinoma with tumor thrombus: report of 19 cases. Surgery; 2002 Mar;131(3):300-10
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical resection combined with chemotherapy for advanced hepatocellular carcinoma with tumor thrombus: report of 19 cases.
  • BACKGROUND: Prognosis of hepatocellular carcinoma (HCC) with tumor thrombus in the main portal vein (MPV), inferior vena cava (IVC), or extrahepatic bile duct (EBD) treated by conventional therapies has been considered poor.
  • This study aimed to evaluate the efficacy of hepatic arterial infusion chemotherapy after surgical resection as an adjuvant therapy or as a treatment for intrahepatic recurrence of HCC with tumor thrombus in MPV, IVC, or EBD.
  • METHODS: Nineteen patients with HCC and tumor thrombus in the MPV, IVC, or EBD who underwent hepatectomy with thrombectomy were reviewed retrospectively.
  • Two patients with postoperative residual tumor thrombus died within 6 months owing to rapid progression of the residual tumor thrombus.
  • Tumors disappeared completely in 3 patients after hepatic arterial infusion chemotherapy with a combination of cisplatinum and 5-fluorouracil, and the longest survival period was 17 years and 11 months in a patient with EBD thrombus.
  • CONCLUSIONS: If hepatic reserve is satisfactory, an aggressive surgical approach combined with chemotherapy seems to be of benefit for patients having HCC with tumor thrombus in the MPV, IVC, or EBD.
  • [MeSH-major] Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Agents / administration & dosage. Carcinoma, Hepatocellular / drug therapy. Carcinoma, Hepatocellular / surgery. Cisplatin / administration & dosage. Fluorouracil / administration & dosage. Liver Neoplasms / drug therapy. Liver Neoplasms / surgery. Thrombosis / complications
  • [MeSH-minor] Adult. Aged. Angiography. Bile Ducts, Extrahepatic / blood supply. Cholangiopancreatography, Endoscopic Retrograde. Combined Modality Therapy. Female. Humans. Infusions, Intra-Arterial. Male. Middle Aged. Neoplasm Recurrence, Local. Postoperative Complications. Survival Analysis

  • MedlinePlus Health Information. consumer health - Blood Clots.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11894035.001).
  • [ISSN] 0039-6060
  • [Journal-full-title] Surgery
  • [ISO-abbreviation] Surgery
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


5. Coss A, Zhou C, Byrne MF, Weiss AA: Relapse of multiple myeloma presenting with biliary obstruction. Can J Gastroenterol; 2010 Apr;24(4):237-8
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A case of a 74-year-old man presenting with symptomatic biliary obstruction two years after the original diagnosis of myeloma is described.
  • Resolution of the pancreatic mass and the associated biliary stricture was observed after radiation and chemotherapy.
  • [MeSH-major] Cholestasis, Extrahepatic / etiology. Common Bile Duct. Multiple Myeloma / complications. Neoplasm Recurrence, Local. Pancreatic Neoplasms / complications
  • [MeSH-minor] Aged. Biopsy, Fine-Needle. Cholangiopancreatography, Endoscopic Retrograde. Diagnosis, Differential. Humans. Male

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Haematol. 2004 Dec;73(6):402-6 [15522061.001]
  • [Cites] Isr Med Assoc J. 2004 Nov;6(11):704-5 [15562814.001]
  • [Cites] Cancer. 1999 Jun 1;85(11):2305-14 [10357398.001]
  • [Cites] AJR Am J Roentgenol. 1989 Jun;152(6):1227-8 [2718859.001]
  • [Cites] Gastrointest Endosc. 1996 Nov;44(5):606-8 [8934171.001]
  • [Cites] Clin Gastroenterol Hepatol. 2009 Mar;7(3):A32 [18848645.001]
  • (PMID = 20431811.001).
  • [ISSN] 0835-7900
  • [Journal-full-title] Canadian journal of gastroenterology = Journal canadien de gastroenterologie
  • [ISO-abbreviation] Can. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Canada
  • [Other-IDs] NLM/ PMC2864618
  •  go-up   go-down


6. Fingas CD, Blechacz BR, Smoot RL, Guicciardi ME, Mott J, Bronk SF, Werneburg NW, Sirica AE, Gores GJ: A smac mimetic reduces TNF related apoptosis inducing ligand (TRAIL)-induced invasion and metastasis of cholangiocarcinoma cells. Hepatology; 2010 Aug;52(2):550-61
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cholangiocarcinoma (CCA) cells paradoxically express tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), a death ligand that, failing to kill CCA cells, instead promotes their tumorigenicity and especially the metastatic behaviors of cell migration and invasion.
  • Second mitochondria-derived activator of caspase (smac) mimetics are promising cancer therapeutic agents that enhance proapoptotic death receptor signaling by causing cellular degradation of inhibitor of apoptosis (IAP) proteins.
  • Treatment with JP1584 inhibited TRAIL-induced NF-kappaB activation as well as TRAIL-mediated up-regulation of the NF-kappaB target gene, matrix metalloproteinase 7 (MMP7).
  • Finally, in a syngeneic rat orthotopic CCA model, JP1584 administration reduced MMP7 messenger RNA levels and extrahepatic metastases.
  • These data support the emerging concept that IAPs are prometastatic and represent targets for antimetastatic therapies.

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Rev Cancer. 2002 Jun;2(6):420-30 [12189384.001]
  • [Cites] Nat Rev Cancer. 2002 Apr;2(4):301-10 [12001991.001]
  • [Cites] Cell Death Differ. 2003 Jan;10(1):45-65 [12655295.001]
  • [Cites] J Cell Sci. 2003 Jul 15;116(Pt 14):3017-26 [12808021.001]
  • [Cites] J Hepatol. 2004 Mar;40(3):472-7 [15123362.001]
  • [Cites] Cancer Res. 2004 May 15;64(10):3517-24 [15150106.001]
  • [Cites] Clin Liver Dis. 2008 Feb;12(1):131-50, ix [18242501.001]
  • [Cites] Hepatology. 2008 Apr;47(4):1178-90 [18081149.001]
  • [Cites] Hepatobiliary Pancreat Dis Int. 2008 Apr;7(2):201-9 [18397859.001]
  • [Cites] Curr Opin Genet Dev. 2008 Feb;18(1):19-26 [18440219.001]
  • [Cites] Mol Cell. 2008 Jun 20;30(6):689-700 [18570872.001]
  • [Cites] Hepatology. 2008 Jul;48(1):308-21 [18536057.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Aug 5;105(31):10895-900 [18667695.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Aug 19;105(33):11778-83 [18697935.001]
  • [Cites] J Biol Chem. 2008 Sep 5;283(36):24295-9 [18621737.001]
  • [Cites] Nat Rev Drug Discov. 2009 Jan;8(1):33-40 [19116625.001]
  • [Cites] Semin Liver Dis. 2004 May;24(2):115-25 [15192785.001]
  • [Cites] Science. 2004 Sep 3;305(5689):1471-4 [15353805.001]
  • [Cites] Mayo Clin Proc. 1995 May;70(5):425-9 [7537346.001]
  • [Cites] Cell. 1995 Dec 29;83(7):1243-52 [8548810.001]
  • [Cites] Lab Invest. 1996 Jan;74(1):303-13 [8569194.001]
  • [Cites] Gastroenterology. 1997 Jan;112(1):269-79 [8978368.001]
  • [Cites] Eur J Cancer. 1998 Jun;34(7):977-86 [9849443.001]
  • [Cites] N Engl J Med. 1999 Oct 28;341(18):1368-78 [10536130.001]
  • [Cites] Gastroenterology. 2005 Jun;128(7):2054-65 [15940637.001]
  • [Cites] Oncogene. 2005 Nov 10;24(49):7381-8 [16044155.001]
  • [Cites] Gastroenterology. 2005 Dec;129(6):2047-57 [16344070.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2006 Jan;290(1):G129-36 [16166346.001]
  • [Cites] Clin Cancer Res. 2006 Apr 15;12(8):2640-6 [16638878.001]
  • [Cites] J Natl Cancer Inst. 2006 Jun 21;98(12):873-5 [16788161.001]
  • [Cites] Oncogene. 2006 Oct 30;25(51):6817-30 [17072330.001]
  • [Cites] Oncogene. 2006 Nov 30;25(56):7434-9 [16751802.001]
  • [Cites] Gynecol Oncol. 2007 May;105(2):481-92 [17292950.001]
  • [Cites] Nat Rev Cancer. 2007 Jun;7(6):415-28 [17508028.001]
  • [Cites] Gut. 2007 Aug;56(8):1124-31 [17470478.001]
  • [Cites] Cancer Cell. 2007 Nov;12(5):445-56 [17996648.001]
  • [Cites] Cell. 2007 Nov 16;131(4):655-8 [18022360.001]
  • [Cites] Cell. 2007 Nov 16;131(4):669-81 [18022362.001]
  • [Cites] Cell. 2007 Nov 16;131(4):682-93 [18022363.001]
  • [Cites] BMC Gastroenterol. 2009;9:30 [19405942.001]
  • [Cites] FASEB J. 2009 Jun;23(6):1625-37 [19141537.001]
  • [Cites] J Clin Invest. 2009 Jun;119(6):1420-8 [19487818.001]
  • [Cites] J Clin Invest. 2009 Jun;119(6):1429-37 [19487819.001]
  • [Cites] Gastroenterology. 2009 Jun;136(7):2365-2376.e1-7 [19272388.001]
  • [Cites] Anticancer Drugs. 2009 Sep;20(8):646-58 [19550293.001]
  • [Cites] Clin Gastroenterol Hepatol. 2009 Nov;7(11 Suppl):S68-78 [19896103.001]
  • [Cites] BMC Cancer. 2009;9:392 [19895686.001]
  • [Cites] Hepatology. 2009 Dec;50(6):1861-70 [19821497.001]
  • [Cites] Cancer Cell. 2010 Jan 19;17(1):53-64 [20129247.001]
  • [Cites] J Clin Invest. 2001 Feb;107(3):241-6 [11160144.001]
  • [Cites] Hepatology. 2001 Jun;33(6):1353-7 [11391522.001]
  • [Cites] Cancer. 2002 Jan 15;94(2):428-34 [11900228.001]
  • [Cites] BMC Cancer. 2002 May 3;2:10 [11991810.001]
  • (PMID = 20683954.001).
  • [ISSN] 1527-3350
  • [Journal-full-title] Hepatology (Baltimore, Md.)
  • [ISO-abbreviation] Hepatology
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA083650-10; United States / NIDDK NIH HHS / DK / DK084567-016281; United States / NCI NIH HHS / CA / R01 CA 39225; United States / NIDDK NIH HHS / DK / R01 DK059427-11; None / None / / R01 DK059427-11; United States / NCI NIH HHS / CA / R01 CA 83650; United States / NIDDK NIH HHS / DK / R01 DK059427; United States / NIDDK NIH HHS / DK / R56 DK059427; United States / NCI NIH HHS / CA / R01 CA083650; United States / NCI NIH HHS / CA / R01 CA039225-26; United States / NIDDK NIH HHS / DK / DK84567; United States / NIDDK NIH HHS / DK / P30 DK084567-016281; United States / NCI NIH HHS / CA / R01 CA039225; United States / NIDDK NIH HHS / DK / DK59427; United States / NIDDK NIH HHS / DK / P30 DK084567
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DIABLO protein, human; 0 / Intracellular Signaling Peptides and Proteins; 0 / Mitochondrial Proteins; 0 / TNF-Related Apoptosis-Inducing Ligand
  • [Other-IDs] NLM/ NIHMS231866; NLM/ PMC2957364
  •  go-up   go-down


9. Jarnagin WR: Cholangiocarcinoma of the extrahepatic bile ducts. Semin Surg Oncol; 2000 Sep-Oct;19(2):156-76
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cholangiocarcinoma of the extrahepatic bile ducts.
  • Malignancies of the biliary tree, particularly the extrahepatic bile ducts, remain difficult clinical problems.
  • Complete resection remains the most effective therapy, but is usually possible in the minority of patients.
  • Palliating the effects of biliary obstruction is thus often the primary therapeutic goal.
  • Chemotherapy and radiation therapy have not been proven to reduce the incidence of recurrence after resection nor to improve survival in patients with unresectable disease.
  • This review focuses on cholangiocarcinoma of the extrahepatic bile ducts.
  • [MeSH-major] Bile Duct Neoplasms / surgery. Bile Ducts, Extrahepatic. Cholangiocarcinoma / surgery
  • [MeSH-minor] Clinical Trials as Topic. Diagnosis, Differential. Humans. Magnetic Resonance Imaging. Neoplasm Staging. Palliative Care. Prognosis

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11126380.001).
  • [ISSN] 8756-0437
  • [Journal-full-title] Seminars in surgical oncology
  • [ISO-abbreviation] Semin Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 135
  •  go-up   go-down


10. Christophides T, Samstein B, Emond J, Bhagat G: Primary follicular lymphoma of the extrahepatic bile duct mimicking a hilar cholangiocarcinoma: case report and review of the literature. Hum Pathol; 2009 Dec;40(12):1808-12
Genetic Alliance. consumer health - Follicular Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary follicular lymphoma of the extrahepatic bile duct mimicking a hilar cholangiocarcinoma: case report and review of the literature.
  • Imaging studies revealed a mass measuring 6.0 x 8.0 cm at the porta hepatis extending to the right lobe of the liver and obstructing the common hepatic duct, causing mild to moderate intrahepatic biliary dilation and variable occlusion of the right portal vein.
  • At laparotomy, an infiltrative neoplasm was noted at the hilum that involved the common bile duct, right and left hepatic ducts, and the right lobe of the liver.
  • Extended right hepatectomy and resection of the extrahepatic bile duct and right portal vein was performed.
  • The patient subsequently received chemotherapy.
  • To the best of our knowledge, this is the third report of a primary extranodal follicular lymphoma of the extrahepatic biliary system.
  • [MeSH-major] Bile Ducts, Extrahepatic / pathology. Lymphoma, Follicular / pathology
  • [MeSH-minor] Bile Duct Neoplasms / pathology. Cholangiocarcinoma / pathology. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Klatskin Tumor / pathology. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19716158.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


11. Zheng SS, Qin YS, Liang TB, Huang DS, Zhang M, Wang WL, Shen Y, Wang JH: [Long-term results of 84 surgically treated patients with extrahepatic bile duct carcinoma]. Zhonghua Zhong Liu Za Zhi; 2005 Sep;27(9):554-6
MedlinePlus Health Information. consumer health - Bile Duct Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Long-term results of 84 surgically treated patients with extrahepatic bile duct carcinoma].
  • OBJECTIVE: Extrahepatic bile duct carcinoma is a rare but dismal malignacy.
  • This study is conducted to show retrospective review and analysis of the correlation between the prognosis and different treatment modalities.
  • RESULTS: Of the 84 patients, 33 had complete resection, 19 palliative resection, 12 exploration alone, and the remaining 20 were treated by chemotherapy and/or radiotherapy.
  • The mean follow-up time was 592 days.
  • The 1-, 3- and 5-year survival rate following complete resection was 76.8%, 52.6% and 30.5% respectively, which was significantly higher than those of palliative surgery or chemotherapy/radiotherapy (P < 0.01).
  • CONCLUSION: The prognosis of extrahepatic bile duct carcinoma remains poor even after complete resection as shown to have a 5-year survival of 30.5%.
  • More effective adjuvant therapy is needed.
  • Early diagnosis and early treatment is still the key to improve the long-term survival of extrahepatic bile duct carcinoma.
  • [MeSH-major] Adenocarcinoma / surgery. Bile Duct Neoplasms / surgery. Bile Ducts, Extrahepatic / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biliary Tract Surgical Procedures / methods. Biliary Tract Surgical Procedures / mortality. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Metastasis. Prognosis. Retrospective Studies. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16438856.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


12. Anderson C, Kim R: Adjuvant therapy for resected extrahepatic cholangiocarcinoma: a review of the literature and future directions. Cancer Treat Rev; 2009 Jun;35(4):322-7
MedlinePlus Health Information. consumer health - Bile Duct Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant therapy for resected extrahepatic cholangiocarcinoma: a review of the literature and future directions.
  • Cholangiocarcinoma is a rare neoplasm originating from the intra- or extrahepatic bile duct epithelium.
  • Adjuvant therapy has the potential to play a crucial role in prolonging survival and local control.
  • Retrospective series have suggested benefit to adjuvant radiation, chemotherapy or concurrent chemo-radiation.
  • The scarce prospective data has not shown a survival benefit to adjuvant therapy.
  • In this article we review and summarize the published data regarding adjuvant therapy for resected extrahepatic cholangiocarcinoma.
  • Prospective, multi-institutional randomized trials are needed to clarify the role of adjuvant therapy in this disease.
  • [MeSH-major] Bile Duct Neoplasms / mortality. Bile Duct Neoplasms / therapy. Bile Ducts, Extrahepatic. Cholangiocarcinoma / mortality. Cholangiocarcinoma / therapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biliary Tract Surgical Procedures / methods. Chemotherapy, Adjuvant. Combined Modality Therapy. Dose-Response Relationship, Drug. Dose-Response Relationship, Radiation. Female. Humans. Male. Neoplasm Staging. Prognosis. Quality of Life. Radiotherapy Dosage. Radiotherapy, Adjuvant. Randomized Controlled Trials as Topic. Risk Assessment. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19147294.001).
  • [ISSN] 1532-1967
  • [Journal-full-title] Cancer treatment reviews
  • [ISO-abbreviation] Cancer Treat. Rev.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 57
  •  go-up   go-down


13. Kim S, Kim SW, Bang YJ, Heo DS, Ha SW: Role of postoperative radiotherapy in the management of extrahepatic bile duct cancer. Int J Radiat Oncol Biol Phys; 2002 Oct 1;54(2):414-9
MedlinePlus Health Information. consumer health - Bile Duct Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of postoperative radiotherapy in the management of extrahepatic bile duct cancer.
  • PURPOSE: To analyze the outcome of postoperative radiotherapy (RT) or chemoradiation for patients with extrahepatic bile duct cancer who had undergone either curative or palliative surgery, and to identify the prognostic factors for these patients.
  • METHODS AND MATERIALS: Between March 1982 and December 1994, 91 patients with extrahepatic bile duct cancer underwent RT at the Department of Therapeutic Radiology, Seoul National University Hospital.
  • All the patients received >40 Gy of external beam RT after surgery.
  • Concurrent 5-fluorouracil was administered during external beam RT in 71 patients, and maintenance chemotherapy was performed in 61 patients after RT completion.
  • On univariate analysis using the Kaplan-Meier product limit method, the use of chemotherapy, performance status, N stage, size of residual tumor, stage, and tumor location were significant prognostic factors.
  • CONCLUSION: Long-term survival can be expected in patients with extrahepatic bile duct cancer who undergo radical surgery and postoperative chemoradiation.
  • [MeSH-major] Bile Duct Neoplasms / radiotherapy. Bile Ducts, Extrahepatic
  • [MeSH-minor] Adult. Aged. Analysis of Variance. Female. Humans. Male. Middle Aged. Neoplasm Staging. Postoperative Period. Prognosis. Proportional Hazards Models. Retrospective Studies. Survival Rate. Treatment Failure

  • Genetic Alliance. consumer health - Extrahepatic bile duct cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12243816.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Kaiho T, Tanaka T, Tsuchiya S, Yanagisawa S, Takeuchi O, Miura M, Saigusa N, Hayasaka A, Matsuzaki O, Miyazaki M: A case of small cell carcinoma of the common bile duct. Hepatogastroenterology; 2005 Mar-Apr;52(62):363-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of small cell carcinoma of the common bile duct.
  • We report a case of small cell carcinoma which occurred in the common bile duct.
  • Computed tomography and ultrasonography showed a mass near the pancreas head and dilatation of the intrahepatic bile ducts.
  • Endoscopic nasobiliary drainage was undertaken, and it revealed obstruction of the common bile duct.
  • The patient was diagnosed preoperatively as having extrahepatic bile duct cancer.
  • Upon laparotomy, a tumor was found to be located in the middle common bile duct.
  • The main trunk of the portal vein and the right hepatic artery were resected concomitantly because of tumor involvement.
  • Postoperative pathological examination revealed well-differentiated papillary adenocarcinoma on the surface of the bile duct lumen, but a large part of the extraductal component was small cell carcinoma.
  • The patient then underwent two postoperative courses of systemic chemotherapy.
  • Nevertheless, she died of cancer recurrence eight months after the operation, which showed that the tumor had a highly lethal nature, with rapid and widespread dissemination.
  • Further therapeutic trials are needed to improve survival in such cases.
  • [MeSH-major] Bile Duct Neoplasms / diagnosis. Carcinoma, Small Cell / diagnosis. Common Bile Duct
  • [MeSH-minor] Aged. Chemotherapy, Adjuvant. Cholangiopancreatography, Magnetic Resonance. Fatal Outcome. Female. Humans. Neoplasm Recurrence, Local. Pancreaticoduodenectomy / methods. Tomography, X-Ray Computed. Ultrasonography

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15816436.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


15. Furuse J, Okusaka T, Ohkawa S, Nagase M, Funakoshi A, Boku N, Yamao K, Yamaguchi T, Sato T: A phase II study of uracil-tegafur plus doxorubicin and prognostic factors in patients with unresectable biliary tract cancer. Cancer Chemother Pharmacol; 2009 Dec;65(1):113-20
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: The purpose of this study was to clarify the safety and efficacy of combination chemotherapy of uracil-tegafur (UFT) and doxorubicin (UFD regimen), and to identify the prognostic factors in patients with unresectable advanced biliary tract cancer who received systemic chemotherapy.
  • METHODS: Patients with histologically or cytologically confirmed, measurable biliary tract cancer, including intrahepatic or extrahepatic cholangiocarcinoma, gallbladder cancer, and ampullary cancer, who were not suitable candidates for surgery, were eligible for the study.
  • The median progression-free survival was 1.6 months, and the overall median survival time was 6.5 months.
  • In the 85 patients who received this UFD chemotherapy in previous and late phase II studies, multivariate analysis revealed the ECOG performance status 1 (P = 0.001), gallbladder as the primary cancer site (P = 0.014), T-factor 4 of the TNM classification (P = 0.035), and elevated serum lactate dehydrogenase levels (P = 0.043) as being associated with a significantly shorter survival.
  • CONCLUSIONS: Combination chemotherapy of UFT and doxorubicin had minimum activity against advanced biliary tract cancer.
  • Performance status was identified as the most important prognostic factor in patients who received systemic chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bile Duct Neoplasms / drug therapy. Biliary Tract Neoplasms / drug therapy. Cholangiocarcinoma / drug therapy. Gallbladder Neoplasms / drug therapy
  • [MeSH-minor] Aged. Ampulla of Vater / pathology. Bile Ducts, Intrahepatic / pathology. Common Bile Duct Neoplasms / diagnosis. Common Bile Duct Neoplasms / drug therapy. Common Bile Duct Neoplasms / mortality. Disease-Free Survival. Doxorubicin / administration & dosage. Female. Humans. L-Lactate Dehydrogenase / blood. Male. Middle Aged. Multivariate Analysis. Neoplasm Staging. Prognosis. Survival Rate. Tegafur / administration & dosage. Treatment Outcome. Uracil / administration & dosage

  • Genetic Alliance. consumer health - Biliary Tract Cancer.
  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19404641.001).
  • [ISSN] 1432-0843
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 1548R74NSZ / Tegafur; 56HH86ZVCT / Uracil; 80168379AG / Doxorubicin; EC 1.1.1.27 / L-Lactate Dehydrogenase
  •  go-up   go-down


16. Hasegawa K, Kubota K, Aoki T, Hirai I, Miyazawa M, Ohtomo K, Makuuchi M: Ischemic cholangitis caused by transcatheter hepatic arterial chemoembolization 10 months after resection of the extrahepatic bile duct. Cardiovasc Intervent Radiol; 2000 Jul-Aug;23(4):304-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ischemic cholangitis caused by transcatheter hepatic arterial chemoembolization 10 months after resection of the extrahepatic bile duct.
  • Ten months prior to TAE the patient had undergone central bisegmentectomy for hepatocellular carcinoma with resection of the extrahepatic bile duct.
  • Eleven days after TAE, he developed suppurative cholangitis and multiple organ failure.
  • Prior surgical ligation of the peribiliary arteries around the extrahepatic bile duct followed by TAE was considered to have played a crucial role in the development of ischemic cholangitis.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Bile Ducts, Extrahepatic / surgery. Bile Ducts, Intrahepatic / blood supply. Chemoembolization, Therapeutic / adverse effects. Cholangitis / chemically induced. Ischemia / chemically induced
  • [MeSH-minor] Angiography. Bile Duct Neoplasms / diagnosis. Bile Duct Neoplasms / drug therapy. Bile Duct Neoplasms / surgery. Carcinoma, Hepatocellular / diagnosis. Carcinoma, Hepatocellular / drug therapy. Carcinoma, Hepatocellular / surgery. Carcinoma, Papillary / diagnosis. Carcinoma, Papillary / drug therapy. Carcinoma, Papillary / surgery. Hepatic Artery. Humans. Injections, Intra-Arterial. Liver Neoplasms / diagnosis. Liver Neoplasms / drug therapy. Liver Neoplasms / surgery. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Recurrence, Local. Neoplasms, Multiple Primary / diagnosis. Neoplasms, Multiple Primary / drug therapy. Neoplasms, Multiple Primary / surgery. Suction. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10960546.001).
  • [ISSN] 0174-1551
  • [Journal-full-title] Cardiovascular and interventional radiology
  • [ISO-abbreviation] Cardiovasc Intervent Radiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down


17. Nanashima A, Yamaguchi H, Shibasaki S, Ide N, Sawai T, Tsuji T, Hidaka S, Sumida Y, Nakagoe T, Nagayasu T: Adjuvant photodynamic therapy for bile duct carcinoma after surgery: a preliminary study. J Gastroenterol; 2004 Nov;39(11):1095-101
MedlinePlus Health Information. consumer health - Bile Duct Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant photodynamic therapy for bile duct carcinoma after surgery: a preliminary study.
  • BACKGROUND: Photodynamic therapy (PDT) is a new palliative option in patients with non-resectable bile duct carcinoma (BDC).
  • Here, we assessed the efficacy of adjuvant photodynamic therapy in eight patients with BDC who underwent surgical resection.
  • METHODS: Five patients had extrahepatic BDC, two had intrahepatic cholangiocarcinoma, and one had ampullary carcinoma.
  • Cancer cells were microscopically detected in the stump of the hepatic duct in six patients, and biliary stenosis caused by remnant tumor was observed in one patient.
  • One patient had tumor recurrence with occlusion of the bile duct.
  • A pulse laser by an eximer dye laser (50-100 J/cm2) with a wavelength of 630 microm was applied through an endoscope to the hepatic stump or tumor lesion.
  • RESULTS: Marked destruction of the tumor and ductal epithelium was observed on day 1 after PDT.
  • After PDT, four patients developed mild dermatitis, but no severe morbidity or mortality was noted.
  • In patients who underwent PDT for the stump, one patient showed distant metastasis at 31 months, and four patients did not show tumor recurrence at 17, 12, 12, and 6 months, respectively.
  • In two patients with occlusion caused by tumor growth, resolution of bile duct stenosis was noted on day 7.
  • These patients showed re-occlusion by tumor at 20 and 8 months.
  • [MeSH-major] Bile Duct Neoplasms / drug therapy. Bile Duct Neoplasms / surgery. Bile Ducts, Extrahepatic. Bile Ducts, Intrahepatic. Cholangiocarcinoma / drug therapy. Cholangiocarcinoma / surgery. Dihematoporphyrin Ether / therapeutic use. Photochemotherapy
  • [MeSH-minor] Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Neoplasm, Residual. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15580404.001).
  • [ISSN] 0944-1174
  • [Journal-full-title] Journal of gastroenterology
  • [ISO-abbreviation] J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 97067-70-4 / Dihematoporphyrin Ether
  •  go-up   go-down


18. Asakura H, Ohtsuka M, Ito H, Kimura F, Ambiru S, Shimizu H, Togawa A, Yoshidome H, Kato A, Miyazaki M: Long-term survival after extended surgical resection of intrahepatic cholangiocarcinoma with extensive lymph node metastasis. Hepatogastroenterology; 2005 May-Jun;52(63):722-4
MedlinePlus Health Information. consumer health - Bile Duct Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 62-year-old man underwent extended left hepatic lobectomy with caudate lobe resection, extrahepatic bile duct resection, portal vein resection and reconstruction, and middle hepatic vein resection and reconstruction with lymph node dissection for a liver tumor that was located in the caudate lobe.
  • These recurrent tumors were completely eliminated by systemic chemotherapy with cisplatin or mitomycin C.
  • The patient is now doing well 6 years and 5 months after surgical treatment.
  • In this case, there was only one tumor, and the preoperative serum carbohydrate antigen 19-9 level was normal.
  • These findings suggested that tumor in the present case was less aggressive, despite the nodal spread.
  • The extensive surgical approach may have contributed to the long-term survival of this patient, while the recurrent tumor was sensitive to antitumoral agents.
  • [MeSH-major] Bile Duct Neoplasms / surgery. Bile Ducts, Intrahepatic / surgery. Cholangiocarcinoma / surgery. Hepatectomy. Lymph Node Excision. Lymphatic Metastasis / pathology
  • [MeSH-minor] Chemotherapy, Adjuvant. Disease-Free Survival. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Retreatment

  • Genetic Alliance. consumer health - Intrahepatic cholangiocarcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15966191.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


19. Dubaniewicz A, Dubaniewicz A: [Cholangiocarcinoma--bile ducts cancer]. Wiad Lek; 2003;56(1-2):57-60
MedlinePlus Health Information. consumer health - Bile Duct Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cholangiocarcinoma--bile ducts cancer].
  • Cholangiocarcinoma (CC) is a malignant neoplasm deriving from intra- and extrahepatic bile ducts.
  • Usually the tumor grows slowly and metastazes late locally and even less frequently extrahepaticly.
  • CC often causes symptoms by blocking the bile ducts, abdominal pain, weight loss, signs of portal hypertension, rare ascites and thrombophlebitis.
  • CC as usually non-vascularized nonencapsulated tumor with a large amount of fibrosis.
  • Recently, FDG positron emission tomography has been suggested to be a sensitive technique in identifying small bile duct cancers.
  • The adjuvant radio- and chemotherapy and transplantation are not satisfactory.
  • Palliative therapy includes surgical biliary-intestinal bypass procedures as well as operative and nonoperative techniques for biliary intestinal drainage.
  • Recently, the local treatment of CC by photodynamic therapy as a palliative strategy is very promising.
  • Ordinary CC is reported as a neoplasm with a poor prognosis.
  • Post resection 5-year survival is affirmed in about 25% of CC, whereas after palliative treatment only 1 year.
  • [MeSH-major] Bile Duct Neoplasms. Bile Ducts, Intrahepatic. Cholangiocarcinoma
  • [MeSH-minor] Adenocarcinoma / complications. Bile Ducts / pathology. Biomarkers, Tumor / analysis. Hepatitis, Chronic / complications. Humans. Liver / pathology. Palliative Care. Prognosis. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12901270.001).
  • [ISSN] 0043-5147
  • [Journal-full-title] Wiadomości lekarskie (Warsaw, Poland : 1960)
  • [ISO-abbreviation] Wiad. Lek.
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 29
  •  go-up   go-down


20. Jarnagin WR, Shoup M: Surgical management of cholangiocarcinoma. Semin Liver Dis; 2004 May;24(2):189-99
MedlinePlus Health Information. consumer health - Bile Duct Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tumors arising from the gallbladder are the most common; those of bile duct origin, or cholangiocarcinoma, are less frequently encountered, constituting approximately 2% of all reported cancers.
  • Twenty to 30% of cholangiocarcinomas originate in the lower bile duct, and approximately 10% arise within the intrahepatic biliary tree and will present as an intrahepatic mass.
  • Complete resection remains the most effective and only potentially curative therapy for cholangiocarcinoma.
  • Distal cholangiocarcinomas, on the other hand, are treated like all periampullary malignancies and typically require pancreaticoduodenectomy.
  • Most patients with cholangiocarcinoma present with advanced disease that is not amenable to surgical treatment, and even with a complete resection, recurrence rates are high.
  • Adjuvant therapy (chemotherapy and radiation therapy) has not been shown clearly to reduce recurrence risk.
  • [MeSH-major] Bile Duct Neoplasms / surgery. Cholangiocarcinoma / surgery
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / surgery. Bile Ducts, Extrahepatic / surgery. Bile Ducts, Intrahepatic / surgery. Hepatectomy. Humans. Neoplasm Staging. Palliative Care

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15192791.001).
  • [ISSN] 0272-8087
  • [Journal-full-title] Seminars in liver disease
  • [ISO-abbreviation] Semin. Liver Dis.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 68
  •  go-up   go-down


21. Saikusa N, Naito S, Iinuma Y, Ohtani T, Yokoyama N, Nitta K: Invasive cholangiocarcinoma identified in congenital biliary dilatation in a 3-year-old boy. J Pediatr Surg; 2009 Nov;44(11):2202-5
MedlinePlus Health Information. consumer health - Bile Duct Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Computed tomography and magnetic resonance imaging demonstrated a dilated extrahepatic bile duct.
  • A diagnosis of Todani's type 1a CBD was made.
  • Intraoperative cholangiography demonstrated the presence of pancreaticobiliary maljunction but could not reveal any tumor lesion in the bile duct.
  • The excision of extrahepatic bile duct and gallbladder and Roux-en-Y hepaticojejunostomy were performed.
  • On gross inspection, we could not find any tumor lesion in the resected specimen.
  • Most of the carcinoma remained within the mucosal layer, and the carcinoma was identified at both the distal and proximal surgical margins of the bile duct.
  • A close follow-up with abdominal computed tomography has been going on without either additional surgery or adjuvant chemotherapy about for 1 year.
  • [MeSH-major] Bile Duct Neoplasms / pathology. Bile Duct Neoplasms / surgery. Cholangiocarcinoma / pathology. Cholangiocarcinoma / surgery. Common Bile Duct / pathology. Common Bile Duct / surgery. Dilatation, Pathologic / congenital. Dilatation, Pathologic / surgery
  • [MeSH-minor] Age Factors. Anastomosis, Roux-en-Y / methods. Bile Ducts, Extrahepatic / radiography. Bile Ducts, Extrahepatic / surgery. Bile Ducts, Intrahepatic / pathology. Bile Ducts, Intrahepatic / surgery. Biliary Tract Surgical Procedures / methods. Child, Preschool. Cholangiography. Humans. Magnetic Resonance Imaging. Male. Neoplasm Invasiveness / radiography. Tomography, X-Ray Computed. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19944233.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Gusani NJ, Balaa FK, Steel JL, Geller DA, Marsh JW, Zajko AB, Carr BI, Gamblin TC: Treatment of unresectable cholangiocarcinoma with gemcitabine-based transcatheter arterial chemoembolization (TACE): a single-institution experience. J Gastrointest Surg; 2008 Jan;12(1):129-37
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of unresectable cholangiocarcinoma with gemcitabine-based transcatheter arterial chemoembolization (TACE): a single-institution experience.
  • BACKGROUND: Survival for patients with unresectable cholangiocarcinoma is reported to range from only 5-8 months without treatment.
  • Systemic chemotherapy has not been shown to significantly improve survival, but newer regimens involving gemcitabine have shown increased response rates.
  • Transcatheter arterial chemoembolization (TACE) has been shown to prolong survival in hepatocellular carcinoma patients, but experience using TACE in the treatment of cholangiocarcinoma is limited.
  • We report our experience treating cholangiocarcinoma with TACE using chemotherapeutic regimens based on the well-tolerated drug gemcitabine.
  • Chemotherapy regimens used for TACE included: gemcitabine only (n=18), gemcitabine followed by cisplatin (n=2), gemcitabine followed by oxaliplatin (n=4), gemcitabine and cisplatin in combination (n=14), and gemcitabine and cisplatin followed by oxaliplatin (n=4).
  • RESULTS: Patients were 59 years of age (range 36-86) and received a median of 3.5 TACE treatments (range 1-16).
  • Nineteen patients (45%) had extrahepatic disease.
  • Grade 3 adverse events (AEs) after TACE treatments were seen in five patients, whereas grade 4 AEs occurred in two patients.
  • Median survival from time of first treatment was 9.1 months overall.
  • Results did not vary by patient age, sex, size of largest initial tumor, or by the presence of extra-hepatic disease.
  • Treatment with gemcitabine-cisplatin combination TACE resulted in significantly longer survival (13.8 months) compared to TACE with gemcitabine alone (6.3 months).
  • CONCLUSIONS: Our report represents the largest series to date regarding hepatic-artery-directed therapy for unresectable cholangiocarcinoma and provides evidence in favor of TACE as a promising treatment modality in unresectable cholangiocarcinoma.
  • Our results suggest that gemcitabine-based TACE is well tolerated and confers better survival when given in combination therapy (with cisplatin or oxaliplatin) for patients with unresectable cholangiocarcinoma.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Bile Duct Neoplasms / therapy. Bile Ducts, Intrahepatic. Chemoembolization, Therapeutic / methods. Cholangiocarcinoma / therapy. Deoxycytidine / analogs & derivatives. Hepatectomy / contraindications
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biopsy. Cholangiopancreatography, Endoscopic Retrograde. Cisplatin / administration & dosage. Drug Therapy, Combination. Female. Follow-Up Studies. Hepatic Artery. Humans. Injections, Intra-Arterial. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Staging. Organoplatinum Compounds / administration & dosage. Retrospective Studies. Ribonucleotide Reductases / antagonists & inhibitors. Survival Rate. Time Factors. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiology. 2002 Jul;224(1):47-54 [12091661.001]
  • [Cites] Semin Oncol. 2002 Dec;29(6 Suppl 20):40-5 [12577232.001]
  • [Cites] Hepatogastroenterology. 2002 Jul-Aug;49(46):900-6 [12143237.001]
  • [Cites] Future Oncol. 2006 Aug;2(4):509-14 [16922617.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92 (3):205-16 [10655437.001]
  • [Cites] J Vasc Interv Radiol. 2002 Sep;13(9 Pt 2):S211-21 [12354839.001]
  • [Cites] Cancer. 2005 Jan 1;103(1):111-8 [15558814.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Jul 15;53(4):969-74 [12095564.001]
  • [Cites] Ann Oncol. 2005;16 Suppl 2:ii93-6 [15958484.001]
  • [Cites] Intern Med J. 2005 Apr;35(4):222-7 [15836500.001]
  • [Cites] World J Gastroenterol. 2005 Feb 28;11(8):1091-5 [15754387.001]
  • [Cites] World J Gastroenterol. 2006 Jan 14;12(2):331-5 [16482640.001]
  • [Cites] Mayo Clin Proc. 1995 May;70(5):425-9 [7537346.001]
  • [Cites] J Vasc Interv Radiol. 2005 Mar;16(3):353-61 [15758131.001]
  • [Cites] J Am Coll Surg. 1998 Oct;187(4):358-64 [9783781.001]
  • [Cites] J Gastrointest Surg. 2006 Jan;10(1):63-8 [16368492.001]
  • [Cites] Eur Radiol. 2007 May;17 (5):1320-30 [17149621.001]
  • [Cites] Cancer. 2005 Apr 1;103(7):1402-7 [15726542.001]
  • [Cites] Surg Oncol. 2005 Dec;14(4):179-93 [16527479.001]
  • [Cites] J Vasc Interv Radiol. 2006 Oct;17(10):1571-93 [17056999.001]
  • [Cites] Hepatology. 2001 Jun;33(6):1353-7 [11391522.001]
  • [Cites] J Cancer Res Clin Oncol. 2006 Nov;132(11):745-55 [16858591.001]
  • [Cites] Can J Gastroenterol. 2005 Dec;19(12):711-6 [16341310.001]
  • [Cites] Biochem Pharmacol. 1972 Jan;21(1):1-16 [4500983.001]
  • [Cites] Eur J Radiol. 2002 Jan;41(1):42-8 [11750151.001]
  • [Cites] Am J Clin Oncol. 2006 Apr;29(2):127-31 [16601429.001]
  • [Cites] J Am Coll Surg. 1997 Nov;185(5):429-36 [9358085.001]
  • [Cites] J Hepatol. 2006 Dec;45(6):856-67 [17030071.001]
  • [Cites] Semin Liver Dis. 2004 May;24(2):177-87 [15192790.001]
  • [Cites] Am Surg. 2002 Apr;68(4):395-7 [11952256.001]
  • [Cites] Cancer J. 2006 Mar-Apr;12(2):113-22 [16630402.001]
  • [Cites] World J Gastroenterol. 2004 Dec 1;10(23):3506-10 [15526374.001]
  • [Cites] J Clin Oncol. 2005 Dec 1;23(34):8739-47 [16314634.001]
  • [Cites] Gastrointest Endosc. 2004 Jul;60(1):68-75 [15229428.001]
  • [Cites] Hepatology. 2003 Feb;37(2):429-42 [12540794.001]
  • [Cites] BMC Cancer. 2002 May 03;2:10 [11991810.001]
  • [Cites] Lancet. 2002 May 18;359(9319):1734-9 [12049862.001]
  • [Cites] Cancer. 2004 Jun 1;100(11):2422-9 [15160347.001]
  • [Cites] Semin Liver Dis. 2004 May;24(2):189-99 [15192791.001]
  • [Cites] J Am Coll Surg. 2006 Jan;202(1):155-68 [16377509.001]
  • [Cites] Lancet. 2005 Oct 8;366(9493):1303-14 [16214602.001]
  • [Cites] J Natl Cancer Inst. 2006 Sep 20;98(18):1272-4 [16985244.001]
  • [Cites] Hepatology. 2002 May;35(5):1164-71 [11981766.001]
  • [Cites] Expert Opin Pharmacother. 2005 Feb;6(2):211-23 [15757418.001]
  • [Cites] Semin Liver Dis. 2004 May;24(2):115-25 [15192785.001]
  • [Cites] AJR Am J Roentgenol. 2003 Sep;181(3):708-10 [12933464.001]
  • [Cites] Gut. 2002 Nov;51 Suppl 6:VI1-9 [12376491.001]
  • (PMID = 17851723.001).
  • [ISSN] 1091-255X
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Grant] United States / NICHD NIH HHS / HD / K12 HD049109
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; EC 1.17.4.- / Ribonucleotide Reductases; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


23. Harder J, Blum HE: [Cholangiocarcinoma]. Praxis (Bern 1994); 2002 Aug 21;91(34):1352-6
MedlinePlus Health Information. consumer health - Bile Duct Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • They are a heterogeneous group of neoplasias that include the most common perihilar or Klatskin tumor (60%), the intrahepatic (peripheral) CCC, the extrahepatic bile duct cancer, the gallbladder cancer and the cancer of the ampulla of Vater.
  • At the time of diagnosis only 20% of patients can be treated by surgery, that offers the only chance for cure.
  • Neither chemotherapy nor radiation therapy improves survival.
  • In patients not eligible for curative surgery prevention or treatment of cholestatis is the main objective.
  • Palliative chemotherapy results in response rates up to 20%.
  • By combining different treatment modalities significant survival can be achieved in some patients.
  • Evidence Based Medicine studies are needed before treatment strategies can be recommended for clinical practice.
  • [MeSH-major] Bile Duct Neoplasms / diagnosis. Bile Ducts, Intrahepatic. Cholangiocarcinoma / diagnosis
  • [MeSH-minor] Gallbladder Neoplasms / diagnosis. Gallbladder Neoplasms / pathology. Hepatic Duct, Common / pathology. Humans. Klatskin Tumor / diagnosis. Klatskin Tumor / pathology. Neoplasm Staging. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12233266.001).
  • [ISSN] 1661-8157
  • [Journal-full-title] Praxis
  • [ISO-abbreviation] Praxis (Bern 1994)
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Switzerland
  • [Number-of-references] 24
  •  go-up   go-down


24. Wiedmann M, Schoppmeyer K, Witzigmann H, Hauss J, Mössner J, Caca K: [Current diagnostics and therapy for carcinomas of the biliary tree and gallbladder]. Z Gastroenterol; 2005 Mar;43(3):305-15
MedlinePlus Health Information. consumer health - Gallbladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Current diagnostics and therapy for carcinomas of the biliary tree and gallbladder].
  • [Transliterated title] Aktuelle Diagnostik und Therapie von Gallengangs- und Gallenblasenkarzinomen.
  • Biliary neoplasms are classified into intra- and extrahepatic cholangiocarcinoma (Klatskin tumour, middle and distal extrahepatic tumours), gallbladder cancer, and ampullary carcinoma.
  • Transformation of normal into malignant bile duct tissue requires a chain of consecutive gene mutations, similar to the adenoma-dysplasia-carcinoma-sequence in colon cancer.
  • Abdominal ultrasound, combined non-invasive magnetic resonance cholangiography/tomography (MRC/MRT), and facultatively endoscopic retrograde cholangiography (ERC) for unclear diagnosis, represent the gold standard for primary diagnosis.
  • In contrast, there has been no clinical benefit for adjuvant and neoadjuvant therapies.
  • For palliation, bile duct stenting and photodynamic therapy are established methods.
  • Radio- and chemotherapy should be reserved for clinical studies.
  • New therapeutic approaches include brachytherapy, the use of modern chemotherapeutics, COX-2- and tyrosine kinase-receptor-inhibitors.
  • [MeSH-major] Bile Duct Neoplasms. Gallbladder Neoplasms
  • [MeSH-minor] Algorithms. Ampulla of Vater. Bile Ducts / pathology. Bile Ducts, Intrahepatic. Biopsy. Brachytherapy. Cholangiocarcinoma / diagnosis. Cholangiocarcinoma / therapy. Cholangiopancreatography, Endoscopic Retrograde. Cholangiopancreatography, Magnetic Resonance. Common Bile Duct Neoplasms / diagnosis. Common Bile Duct Neoplasms / therapy. Cyclooxygenase Inhibitors / therapeutic use. Gallbladder / pathology. Hepatectomy. Hepatic Duct, Common. Humans. Klatskin Tumor / diagnosis. Klatskin Tumor / therapy. Magnetic Resonance Imaging. Neoplasm Staging. Palliative Care. Retrospective Studies. Risk Factors. Stents. Time Factors

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Z Gastroenterol. 2005 May;43(5):473-5 [15871071.001]
  • (PMID = 15765304.001).
  • [ISSN] 0044-2771
  • [Journal-full-title] Zeitschrift für Gastroenterologie
  • [ISO-abbreviation] Z Gastroenterol
  • [Language] ger
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Cyclooxygenase Inhibitors
  • [Number-of-references] 153
  •  go-up   go-down


25. Schleicher UM, Staatz G, Alzen G, Andreopoulos D: Combined external beam and intraluminal radiotherapy for irresectable Klatskin tumors. Strahlenther Onkol; 2002 Dec;178(12):682-7
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Radiotherapy can be used for palliative treatment.
  • PATIENTS AND METHODS: 30 patients were treated for extrahepatic proximal bile duct cancer.
  • Our schedule consisted of external beam radiotherapy (median dose 30 Gy) and a high-dose-rate brachytherapy boost (median dose 40 Gy) delivered in four of five fractions, which could be applied completely in twelve of our patients.
  • 15 patients in the brachytherapy and nine patients in the non-brachytherapy group received additional low-dose chemotherapy with 5-fluorouracil.
  • The effect was obvious in patients receiving a brachytherapy dose above 30 Gy, and in those without jaundice at the beginning of radiotherapy (p < 0.05).
  • CONCLUSIONS: The poor prognosis in patients with advanced Klatskin's tumors may be improved by combination therapy, with the role of brachytherapy and chemotherapy still to be defined.
  • Our results suggest that patients without jaundice should be offered brachytherapy, and that a full dose of more than 30 Gy should be applied.
  • [MeSH-major] Bile Duct Neoplasms / radiotherapy. Brachytherapy. Hepatic Duct, Common. Klatskin Tumor / radiotherapy
  • [MeSH-minor] Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Combined Modality Therapy. Female. Fluorouracil / administration & dosage. Fluorouracil / adverse effects. Humans. Male. Middle Aged. Neoplasm Staging. Palliative Care. Survival Rate

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12491056.001).
  • [ISSN] 0179-7158
  • [Journal-full-title] Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]
  • [ISO-abbreviation] Strahlenther Onkol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] U3P01618RT / Fluorouracil
  •  go-up   go-down


26. Suzuki S, Sakaguchi T, Yokoi Y, Okamoto K, Kurachi K, Tsuchiya Y, Okumura T, Konno H, Baba S, Nakamura S: Clinicopathological prognostic factors and impact of surgical treatment of mass-forming intrahepatic cholangiocarcinoma. World J Surg; 2002 Jun;26(6):687-93
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathological prognostic factors and impact of surgical treatment of mass-forming intrahepatic cholangiocarcinoma.
  • The clinicopathological characteristics relevant to prognosis after surgical treatment of intrahepatic cholangiocarcinoma (ICC) remain unclear.
  • Resection of the extrahepatic bile duct was performed in 14 patients, and reconstruction of the portal vein was accomplished in 5 patients.
  • The estimated 5-year survival rate after surgery for mass-forming ICC was 28%, with median survival time of 18 months.
  • Hepatectomy with resection of the extrahepatic bile duct and systematic lymphadenectomy yields a good chance for prolonged survival for patients with mass-forming ICC when the lesion is singular and LN metastasis is limited to a regional LN.
  • Because the presence of intrahepatic metastasis was closely related to a poor prognosis in patients with mass-forming ICC, efficacious chemotherapy would be needed to control development of the lesion.
  • [MeSH-minor] Aged. Female. Hepatectomy / methods. Humans. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Recurrence, Local. Prognosis. Retrospective Studies. Risk Factors. Survival Analysis. Survivors

  • Genetic Alliance. consumer health - Intrahepatic cholangiocarcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Surg. 1996 Nov;83(11):1517-21 [9014664.001]
  • [Cites] Cancer. 1989 Dec 1;64(11):2226-32 [2553242.001]
  • [Cites] Surgery. 1992 Jun;111(6):617-22 [1317612.001]
  • [Cites] World J Surg. 1995 Jan-Feb;19(1):83-8 [7740815.001]
  • [Cites] Ann Surg. 1996 Oct;224(4):463-73; discussion 473-5 [8857851.001]
  • [Cites] Ann Surg. 1992 Apr;215(4):344-9 [1558415.001]
  • [Cites] Br J Surg. 1998 Sep;85(9):1206-9 [9752860.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 1999;6(2):142-8 [10398901.001]
  • [Cites] Eur J Surg Oncol. 1996 Apr;22(2):186-8 [8608839.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 1998;5(1):41-7 [9683753.001]
  • [Cites] Ann Surg. 1998 Jan;227(1):70-9 [9445113.001]
  • [Cites] Hum Pathol. 1988 Oct;19(10):1228-34 [2844646.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 1999;6(2):108-16 [10398896.001]
  • [Cites] Cancer. 1977 Jan;39(1):232-46 [64293.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 1999;6(2):122-7 [10398898.001]
  • [Cites] Hepatogastroenterology. 1990 Apr;37(2):176-81 [2160420.001]
  • [Cites] HPB Surg. 1992;5(2):95-101; discussion 101-2 [1319194.001]
  • [Cites] J Gastroenterol Hepatol. 1994 Sep-Oct;9(5):442-6 [7827293.001]
  • [Cites] Cancer. 1998 Nov 1;83(9):1923-9 [9806650.001]
  • [Cites] Ann Surg. 1990 Mar;211(3):277-87 [2155591.001]
  • [Cites] J Surg Oncol. 1995 May;59(1):40-4 [7745976.001]
  • [Cites] Cancer. 1995 Dec 15;76(12):2449-56 [8625070.001]
  • [Cites] Arch Surg. 1995 Oct;130(10):1073-8 [7575119.001]
  • (PMID = 12053220.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down






Advertisement